For decades, families carrying rare genetic mutations have lived under the near-certain shadow of early-onset Alzheimer's disease. Now, a clinical trial at Washington University School of Medicine has offered the first evidence that removing amyloid from the brain years before symptoms appear can delay — and perhaps forestall — the disease's arrival, cutting the risk of dementia in half among those treated longest. The findings, published in The Lancet Neurology, do not promise a cure, but they shift the horizon of what prevention might mean: not merely slowing a disease already in motion, but
Early amyloid-removal drug cuts Alzheimer's dementia risk in half for genetic carriers
Two participants developed severe amyloid-related imaging abnormalities requiring drug discontinuation, though they recovered; no deaths occurred.
Early removal of amyloid, years before symptoms, appears to buy time.
Mark
Why does it matter that these people carry genetic mutations? Aren't they just a tiny fraction of Alzheimer's cases?
Mimi
They are rare, yes—maybe one in a thousand families. But they're a window into how the disease works in everyone. Both genetic and common Alzheimer's start the same way: amyloid building up silently in the brain for decades. What we learn from stopping it early in these families tells us what might work for millions.
Mark
So the drug cut the risk in half. That sounds good, but half of these people will still get dementia, right?
Mimi
That's the honest reading. But remember: these people were destined to get it. The drug didn't cure them. It delayed when symptoms arrive. If you can buy someone ten extra years of healthy cognition, that changes their life—their career, their relationships, their independence.
Mark
The study was cut short because the drug failed in symptomatic patients. How do you interpret that?
Mimi
It's telling. The drug works best when you give it years before symptoms appear, when the brain is still clearing amyloid efficiently. Once cognitive decline has started, the damage may be too advanced. That's why prevention—not treatment—is the real frontier.
Mark
Two people got severe brain bleeds. Isn't that a serious problem?
Mimi
It happened in 30 percent of the group, though most had no symptoms. Two were severe enough to stop treatment, and both recovered. That's a real safety signal researchers have to take seriously. But in a disease that's otherwise inevitable, some people are willing to accept that risk for the chance to stay cognitively normal.
Mark
What happens to these people now?
Mimi
They're on a different drug, lecanemab. Researchers are watching to see how long the delay holds, and whether even younger people—those with genetic mutations but no brain changes yet—can prevent the disease from ever starting. We're still in the early chapters of this story.
El Pulso
- People born with mutations that virtually guarantee Alzheimer's in their 30s, 40s, or 50s have long had no recourse — this trial is the first to suggest that fate can be interrupted.
- After eight years of treatment with the anti-amyloid antibody gantenerumab, 22 symptom-free participants saw their dementia risk fall from near-certain to roughly a coin flip.
- The trial was cut short in 2023 when Roche discontinued gantenerumab after it failed in symptomatic patients, leaving researchers to pivot mid-study and transition participants to alternative drugs.
- Side effects were real — nearly a third of participants developed brain imaging abnormalities, and two required stopping treatment — though all recovered and no deaths occurred.
- The study is now expanding its reach, enrolling carriers as young as 18 in prevention trials that begin before any molecular trace of the disease has taken hold.
For decades, families carrying rare genetic mutations have lived under the near-certain shadow of early-onset Alzheimer's disease. Now, a clinical trial at Washington University School of Medicine has offered the first evidence that removing amyloid from the brain years before symptoms appear can delay — and perhaps forestall — the disease's arrival, cutting the risk of dementia in half among those treated longest. The findings, published in The Lancet Neurology, do not promise a cure, but they shift the horizon of what prevention might mean: not merely slowing a disease already in motion, but intervening in the long silence before it speaks.
In the basement of Washington University School of Medicine in St. Louis, researchers have spent years following people who carry a rare and cruel inheritance: genetic mutations that make Alzheimer's disease not a risk, but a near-certainty, arriving in their 30s, 40s, or 50s. What happened to 22 of them over eight years of treatment with an experimental antibody called gantenerumab has changed what scientists believed was possible. Their risk of developing dementia dropped from essentially inevitable to roughly even odds.
Published in The Lancet Neurology in March 2025, the findings mark the first time a clinical trial has demonstrated that clearing amyloid plaques from the brain — years before any symptoms emerge — can actually delay when the disease takes hold. The participants had no cognitive problems when treatment began. Some are now at or past the age their family history predicted symptoms would arrive. They remain cognitively intact.
The Knight Family DIAN-TU trial began in 2012 as the world's first Alzheimer's prevention study, enrolling 73 mutation carriers who were either symptom-free or showing only mild decline. When the original trial ended in 2020, gantenerumab had lowered amyloid levels but showed no clear cognitive benefit — because the symptom-free group hadn't declined regardless of whether they received drug or placebo. An extension study followed, this time without a placebo arm, comparing treated participants to untreated carriers from a related observational study.
The extension was cut short in mid-2023 when Roche discontinued gantenerumab after Phase 3 trials in symptomatic patients failed. By then, the 22 longest-treated participants had averaged eight years on the drug — and the 50 percent reduction in dementia risk had become visible. Senior researcher Randall Bateman was careful about certainty: some participants may yet develop symptoms, which would reduce the apparent benefit. But the signal, he said, is unmistakable.
The findings lend strong support to the amyloid hypothesis — the idea that amyloid accumulation is the first domino in Alzheimer's, and that removing it early can prevent the cascade from ever beginning. Because genetic early-onset Alzheimer's and the common late-onset form both begin with amyloid accumulating roughly two decades before memory problems surface, Bateman believes prevention strategies could eventually reach the general population.
The drug carried risks: about 30 percent of participants developed amyloid-related brain imaging abnormalities, most of which resolved without symptoms. Two participants developed severe cases and had to stop treatment; both recovered. No deaths occurred.
Gantenerumab is no longer in development, but the research continues. Most participants have transitioned to lecanemab, an anti-amyloid drug approved by the FDA in 2023. A new trial is now enrolling carriers as young as 18 — up to 25 years before expected symptom onset — asking whether stopping the disease before it even begins molecularly can prevent it from ever taking hold at all.
In the basement of Washington University School of Medicine in St. Louis, researchers have been tracking a small group of people who know with near certainty that Alzheimer's disease is coming for them. They carry rare genetic mutations that virtually guarantee the disease will arrive in their 30s, 40s, or 50s—a biological sentence handed down through families. What happened to 22 of them over eight years of treatment with an experimental drug called gantenerumab has upended what scientists thought possible: the risk of developing dementia dropped from essentially inevitable to roughly even odds.
The study, published in The Lancet Neurology on March 19, represents the first time a clinical trial has shown that removing amyloid plaques from the brain years before any symptoms appear can actually delay when the disease takes hold. These 22 participants had no cognitive problems when the study began. They received gantenerumab—an antibody designed to clear amyloid buildup—for an average of eight years. By the time researchers analyzed the data, the drug had cut their dementia risk in half. Some of these people are now at or past the age when their family history predicted symptoms should have emerged. They remain cognitively intact.
The Knight Family DIAN-TU trial, as it's known, began in 2012 as the world's first Alzheimer's prevention study. It enrolled 73 people carrying dominant genetic mutations that cause the brain to overproduce amyloid—the sticky protein that accumulates in Alzheimer's disease. All participants had either no cognitive decline or very mild decline, and all fell within a window of 15 years before to 10 years after their predicted age of disease onset. When the original trial ended in 2020, gantenerumab had lowered amyloid levels in the brain, but researchers saw no clear benefit in cognition because the symptom-free group hadn't declined, whether they received drug or placebo. That ambiguous result prompted an extension study.
In the extension, all eligible participants received gantenerumab—there was no placebo control group. Researchers instead compared the treated group to untreated carriers from a related observational study and to placebo-treated participants who didn't continue. The extension was supposed to run three years but was cut short in mid-2023 when Roche and Genentech discontinued gantenerumab development after their Phase 3 trials in symptomatic patients failed to slow cognitive decline. By then, the average participant had been treated for 2.6 years. The longest-treated group—those 22 who started symptom-free and stayed in the study longest—had received the drug for eight years on average.
The 50 percent reduction in dementia risk is calculated not just by counting who developed symptoms, but by measuring when symptoms emerged relative to each person's predicted age of onset. The effect size could shift as time passes. Some participants are now beyond their expected disease onset and remain healthy; the longer they stay symptom-free, the stronger the effect appears. Others may yet develop symptoms, which would reduce the overall benefit. Randall Bateman, the senior researcher leading the work, emphasized the uncertainty: "We don't yet know how long they will remain symptom-free—maybe a few years or maybe decades." But the signal is unmistakable. Early removal of amyloid, years before the brain shows signs of cognitive damage, appears to buy time.
The findings validate the amyloid hypothesis—the idea that amyloid accumulation is the first domino in Alzheimer's disease, and that stopping it early can prevent symptoms from ever arising. Both early-onset genetic Alzheimer's and the common late-onset form begin with amyloid slowly collecting in the brain roughly two decades before memory problems surface. Every major finding from these genetic early-onset families has eventually been replicated in late-onset disease. If that pattern holds, Bateman said, prevention strategies could eventually be available for the general population. "One day soon, we may be delaying the onset of Alzheimer's disease for millions."
The drug did carry risks. Gantenerumab and other anti-amyloid antibodies can cause amyloid-related imaging abnormalities—tiny brain bleeds or localized swelling visible on scans. In this extension, 30 percent of participants showed these abnormalities, up from 19 percent in the original trial, likely due to higher doses. Most cases caused no symptoms and resolved on their own. Two participants developed severe abnormalities and had to stop treatment; both recovered. There were no deaths. The safety profile remained consistent with other gantenerumab trials.
Gantenerumab is no longer being developed, but the work continues. Most extension participants have switched to lecanemab, an anti-amyloid drug the FDA approved in 2023 for symptomatic Alzheimer's patients. A new trial called the Knight Family DIAN-TU Amyloid Removal Trial is underway, funded initially by the Alzheimer's Association, with an NIH grant pending. Meanwhile, researchers are launching even earlier intervention studies. The Primary Prevention Trial is enrolling people as young as 18 who carry dominant mutations but have few or no detectable Alzheimer's changes in their brains—up to 25 years before symptoms are expected. The question now is whether stopping the disease before it even begins molecularly can prevent it from ever taking hold at all.
Citas Notables
We don't yet know how long they will remain symptom-free—maybe a few years or maybe decades. What we know is that it's possible at least to delay the onset of symptoms and give people more years of healthy life.— Randall J. Bateman, MD, senior author and neurology professor at Washington University School of Medicine
One day soon, we may be delaying the onset of Alzheimer's disease for millions.— Randall J. Bateman, MD
Quieres la nota completa?
Lee el original en News-Medical.net ↗
Health & Medicine